Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RPTR-168 |
Synonyms | |
Therapy Description |
RPTR-168 are autologous T lymphocytes that are targeted against multiple tumor associated antigens (TAAs) and attached to the interleukin IL-12, which bind to tumor cells expressing the TAAs, potentially leading to cytotoxic T-cell mediated killing of these cells and the activation of the anti-tumor immune response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RPTR-168 | RPTR168|RPTR 168 | RPTR-168 are autologous T lymphocytes that are targeted against multiple tumor associated antigens (TAAs) and attached to the interleukin IL-12, which bind to tumor cells expressing the TAAs, potentially leading to cytotoxic T-cell mediated killing of these cells and the activation of the anti-tumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04762225 | Phase I | RPTR-168 | RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors (HNSCC, Cervical) and Melanoma | Terminated | USA | 0 |